Zacks Investment Research upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a hold rating to a buy rating in a research note published on Monday. They currently have $82.00 price target on the biotechnology company’s stock.
According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Several other research firms also recently issued reports on ENTA. Royal Bank of Canada boosted their price objective on shares of Enanta Pharmaceuticals to $78.00 and gave the stock a sector perform rating in a research note on Thursday, February 8th. JPMorgan Chase & Co. downgraded shares of Enanta Pharmaceuticals from an overweight rating to a neutral rating in a research note on Thursday, February 8th. BidaskClub downgraded shares of Enanta Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Saturday, February 10th. Finally, TheStreet upgraded shares of Enanta Pharmaceuticals from a c+ rating to a b- rating in a research note on Wednesday, December 13th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $57.40.
Enanta Pharmaceuticals (ENTA) traded up $1.66 on Monday, reaching $81.34. 196,400 shares of the company’s stock traded hands, compared to its average volume of 243,806. Enanta Pharmaceuticals has a 12 month low of $27.24 and a 12 month high of $95.91. The stock has a market capitalization of $1,526.72, a P/E ratio of 41.50 and a beta of 1.04.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, November 20th. The biotechnology company reported $1.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a return on equity of 13.33% and a net margin of 26.35%. The business had revenue of $75.93 million for the quarter, compared to analysts’ expectations of $73.80 million. During the same quarter in the prior year, the firm earned ($0.09) earnings per share. Enanta Pharmaceuticals’s quarterly revenue was up 491.3% compared to the same quarter last year. sell-side analysts anticipate that Enanta Pharmaceuticals will post 0.86 EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in ENTA. Farallon Capital Management LLC boosted its stake in shares of Enanta Pharmaceuticals by 124.3% in the fourth quarter. Farallon Capital Management LLC now owns 925,000 shares of the biotechnology company’s stock valued at $54,279,000 after purchasing an additional 512,667 shares during the period. Millennium Management LLC purchased a new position in shares of Enanta Pharmaceuticals in the fourth quarter valued at $12,959,000. Dimensional Fund Advisors LP boosted its stake in shares of Enanta Pharmaceuticals by 34.3% in the second quarter. Dimensional Fund Advisors LP now owns 554,777 shares of the biotechnology company’s stock valued at $19,961,000 after purchasing an additional 141,688 shares during the period. First Manhattan Co. boosted its stake in shares of Enanta Pharmaceuticals by 14.5% in the fourth quarter. First Manhattan Co. now owns 1,084,200 shares of the biotechnology company’s stock valued at $63,620,000 after purchasing an additional 137,100 shares during the period. Finally, Franklin Resources Inc. boosted its stake in shares of Enanta Pharmaceuticals by 58.9% in the fourth quarter. Franklin Resources Inc. now owns 317,700 shares of the biotechnology company’s stock valued at $18,643,000 after purchasing an additional 117,700 shares during the period. Institutional investors and hedge funds own 68.04% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/02/16/enanta-pharmaceuticals-enta-rating-increased-to-buy-at-zacks-investment-research.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.